After Treatment

Keep observing after the deepest oneirogenic phase resolves. Noribogaine lasts much longer than parent ibogaine, QT changes persisted beyond 24 hours in some monitored participants, severe poisoning cases show abnormalities lasting days, and ataxia, hydration, sleep, psychiatric state, and withdrawal can all continue to evolve. The literature has not established one observation time for every exposure. Follow the trajectory and unresolved risks.

Discharge is a handoff to the next setting. Before the person leaves, the team should be able to explain why the cardiac trajectory is acceptable, why mobility and hydration are safe, why mental status is stable enough, how medications will restart or change, what the withdrawal and relapse plan is, who is supervising transport, and who owns the next contact.

Practice note: make the discharge decision from the whole trajectory. Worsening ECG findings, new arrhythmia, syncope, unsafe gait, persistent vomiting, altered mental status, or an unfinished addiction care plan should keep the person in monitored care or trigger a higher level evaluation.

Leaving before the team recommends discharge is a foreseeable event and should be planned for before dosing. Historical GITA and New Zealand resources used early-release forms. A modern approach should focus less on liability waivers and more on capacity, informed refusal, harm reduction, documentation, and keeping the person connected to care.

PARTICIPANT: Wanting to leave should not automatically be interpreted as resistance. Ask what is driving the decision, what risks remain, what alternatives exist, and what would make the next step safer. If you are legally capable of deciding, the team should explain the risk without humiliating, threatening, or unlawfully detaining you.

FACILITATOR: Keep the conversation calm, bring the responsible clinician into the decision, preserve dignity, and help identify transport, support, medication, mobility, or environmental problems contributing to the request. Do not independently decide capacity or medical discharge.

CLINICAL TEAM / PROGRAM: assess capacity, unresolved medical and psychiatric risk, safe transport, alternatives, emergency instructions, documentation, and any legal obligations. A program should have a written early-departure process before the first participant asks to leave.

A discharge plan should therefore identify what has not fully normalized, who owns each follow up question, which symptoms require urgent evaluation, and how quickly the team will make contact again. A participant with a completely uncomplicated course does not need the same follow up intensity as somebody discharged after marked QT prolongation, persistent vomiting, severe ataxia, medication changes, prolonged insomnia, or psychiatric activation.

The safest follow up is problem based. Cardiac abnormalities should have an explicit medical follow up plan. Medication changes need a responsible prescriber. OUD needs overdose prevention and rapid linkage to ongoing treatment. Persistent insomnia, mania, psychosis, suicidality, severe dissociation, or functional deterioration needs timely psychiatric care. No amount of “integration” should be used to delay ordinary medical or psychiatric evaluation.

Contemporary provider sources describe post-treatment variability, but they do not use the same language consistently. Enginsoy records one provider using “grey day” for a temporary emotional downturn around days five to six after flood dosing, while other providers describe an “afterglow” marked by unusual clarity, energy, or certainty. Ambio currently uses “Gray Day” differently, for the day immediately after treatment, when rest, exhaustion, sleeplessness, emotional processing, and supportive recovery may be prominent. The shared lesson is variability; the label itself is program-specific.

These are field-practice phenomenology and program language, not validated syndromes or fixed timelines. They are useful because they change what a facilitator watches for. A temporary low period should not automatically be interpreted as treatment failure, and a powerful positive state should not be treated as proof of durable recovery. Track sleep, mood, judgment, impulsivity, craving, substance exposure, suicidality, mania or psychosis symptoms, and ordinary functioning. Encourage major life decisions to survive contact with time, sleep, and the person’s usual environment.

Plan the first environment after discharge with the same seriousness as the treatment room. Transportation should not depend on the participant driving. Access to food, fluids, medications, sleep, bathroom safety, naloxone when relevant, and a person who knows what symptoms require help should be established before departure. Major relationship confrontations, financial decisions, abrupt medication changes, or other irreversible actions deserve additional time when the person remains sleep deprived, emotionally activated, or cognitively altered. No fixed number of days is supported for all participants; the plan should follow actual function and recovery.

Community ibogaine guidelines historically recommended extended on-site observation and weeks of follow-up contact, while experienced providers repeatedly emphasized that the treatment event alone was not enough. Those exact durations should not be treated as validated universal rules, but the operational lesson is sound: discharge should hand the person into an existing support structure rather than into an empty calendar.

The place a participant returns to is part of the treatment plan. The New Zealand integrated-care model explicitly considered inadequate home environment a reason for further investigation before acceptance. This lens treats that as a recovery and safety variable, not a moral judgment. Housing instability, interpersonal violence, immediate drug availability, isolation, caregiving demands, inaccessible stairs, or lack of transportation can turn a technically successful discharge into a predictable failure. Identifying an unstable return environment should trigger support planning, harm reduction, referral, or a safer discharge plan before it becomes a reason to exclude someone simply because they have fewer resources.

Before discharge, confirm the actual destination, who will be present, whether the participant can safely manage mobility and self-care there, how medications will be handled, what happens if craving or psychiatric symptoms intensify, and how urgent medical help can be reached. If the return environment is unsafe, solve as much of that problem as possible before treatment rather than discovering it after the person is physiologically depleted and trying to travel home.

Ibogaine can reduce withdrawal and craving for some people, but OUD and relapse risk continue after the session. Loss of opioid tolerance can make a return to use especially dangerous. Plan continuing addiction care before administration and confirm it again before discharge. Buprenorphine and methadone remain evidence based options when clinically appropriate, and naloxone, overdose education, pain planning, and rapid follow up belong in the discharge conversation.

Talk openly about methadone and buprenorphine when they fit the person’s clinical situation, even if the person came to ibogaine hoping to be completely opioid free. These medications have strong evidence for reducing mortality and improving retention in care. Keep the conversation noncoercive and explain how quickly tolerance can fall during abstinence.

For alcohol, benzodiazepines, stimulants, cannabis, and polysubstance use, build continuing care around the diagnosed disorder and the person’s actual risks. Alcohol and benzodiazepine dependence may require medically managed withdrawal. Stimulant use disorder often benefits from behavioral treatment and contingency management. Treat cooccurring psychiatric illness, trauma, chronic pain, sleep disturbance, and social instability directly; the ibogaine experience does not reliably resolve those problems on its own.

GENERAL ADDICTION MEDICINE: ASAM 2020 and the broader OUD literature provide the strongest continuing care evidence. Sordo et al. found lower mortality during opioid agonist treatment than during periods out of treatment. Strang et al. documented overdose risk after tolerance loss following detoxification. These data come from addiction medicine rather than ibogaine trials, but they speak directly to the risk created when an opioid dependent person becomes abstinent.

A relapse-prevention plan should be built before discharge, not improvised after craving returns. I.ACT’s 2014 integrated-care materials included a formal relapse-prevention worksheet; Kroupa and Wells challenged the early “one treatment cure” narrative; Enginsoy’s provider interviews likewise emphasized ongoing support. The modern version should connect evidence-based addiction care with the participant’s own warning signs and recovery environment.

The days and weeks after ibogaine can bring relief, exhaustion, poor sleep, grief, intense autobiographical material, unusual beliefs, relationship shifts, and a sudden sense that major life decisions are obvious. Make room for meaning while still watching function. A powerful spiritual or psychological experience can occur alongside mania, psychosis, medication withdrawal, or deterioration driven by prolonged sleep loss.

Some people leave with a coherent story. Some have fragments, disturbing material, or almost no visions at all. Early integration should stay grounded in ordinary functioning: sleep, hydration, medications, withdrawal and craving, psychiatric stability, relationships, and the ability to return to daily life. Meaning can unfold over time.

Let the participant keep authorship over what happened. If they describe an ancestor, entity, divine message, or morally charged vision, explore the experience and what it means to them. If they later question it, leave room for that too. The clinical job is to stay curious, track function and safety, and avoid turning the clinician’s metaphysical beliefs into part of the record.

Where the Eight Circuit Lens is used, ontological humility is the useful principle. Help the participant examine the experience while leaving metaphysical conclusions with the participant.

PARTICIPANT: If the outcome is disappointing, tell the team what did and did not change. Do not stop medical or psychiatric treatment because a hoped-for effect did not occur, and do not assume that relapse means the entire experience was meaningless. The next step may be addiction treatment, medication, psychotherapy, pain care, psychiatric care, social support, or simply more time and reassessment.

FACILITATOR: Avoid rescuing the treatment narrative by inventing hidden success. Assess withdrawal, craving, mood, sleep, safety, function, relapse risk, expectations, and available support. Help the participant identify the next evidence-based or personally meaningful step without forcing a positive interpretation.

PROGRAM / SYSTEM: marketing and consent materials should not imply guaranteed visions, guaranteed detoxification, permanent abstinence, trauma cure, spiritual certainty, or a one-treatment solution. Follow-up pathways must exist for people whose outcomes are incomplete or negative.

FIELD PRACTICE POSITION: adjunctive practices should support the participant’s recovery plan rather than justify claims that a particular ceremony, therapy, or integration package is necessary for ibogaine to “work.” Comparative evidence on timing, intensity, and optimal combinations remains limited.

NAMED CONTEMPORARY PROVIDER COMMENTARY: Ambio co-founder Trevor Millar publicly describes an “A5 to Thrive” integration heuristic centered on daily practices such as meditation, exercise or movement, nutrition, learning, and deliberately filling the behavioral space left when an old pattern is interrupted. Retain this as an attributed integration heuristic, not a validated ibogaine aftercare protocol or evidence that any specific daily practice improves outcome.

EXPERT PRACTICE: This documentation structure adapts ordinary clinical recording principles to the failure modes seen in ibogaine care and to the Reports and Records function of the Global Competencies. A prospective ibogaine specific documentation standard has not been validated.

Palitsky and colleagues proposed a structured way to assess adverse events in psychedelic assisted therapies. The useful idea here is simple: detect the event, describe it carefully, stay cautious about attribution, follow the course, and record enough detail for later review. Ibogaine adds more medical complexity because rhythm, repolarization, withdrawal, product uncertainty, and delayed toxicity may be prominent.

GENERAL PSYCHEDELIC SAFETY FRAMEWORK: Palitsky et al. (2024) supports systematic adverse event ascertainment. The framework is adapted for ibogaine; emergency thresholds come from the relevant ibogaine evidence and broader specialty standards.

Jonathan Dickinson has described the early Global Ibogaine Therapy Alliance safety meetings as functioning much like morbidity and mortality conferences: providers discussed deaths and adverse events, examined emerging forensic evidence, and tried to convert what was learned into practical risk reduction. That history supports an open learning model in which serious events, near misses, and protocol failures become structured inputs to safer practice rather than private institutional memory.

A contemporary example comes from Ambio. On 21 January 2026, the program publicly disclosed that a patient had died while participating in its Detoxification Program and stated that the event and the changing street-drug environment led to enhanced screening, longer detoxification program durations, and a minimum 21-day stay for people using fentanyl before treatment. The public statement did not disclose the cause of death. The 21-day requirement therefore belongs here as an Ambio program-level quality-improvement response, not as a validated universal fentanyl washout, stabilization interval, or eligibility rule.

FIELD PRACTICE / QI BOUNDARY: transparent protocol revision can be documented as a named program response even when the event does not establish causality and the revised local rule has not been comparatively validated.